NEW YORK, May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GoodRx investors who were adversely affected by alleged securities fraud between September 23, 2022 and November 8, 2022. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/goodrx-lawsuit-submission ...

NEW YORK, May 21, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the "Class Period"), of the important June 21, 2024 lead plaintiff deadline. WHAT TO DO NEXT: To join the GoodRx class action, go to https://rosenlegal.com/submit-form/? case_id=24355 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for info ...

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by tel ...

The class action concerns whether GoodRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged ...

Group 1: GoodRx Holdings Inc (GDRX) - GoodRx stock is experiencing a significant increase, up 8.8% to $7.91, following an upgrade from Raymond James to "outperform" and a price target increase from $14 to $16 [1] - The stock has risen 18.2% since the beginning of the year, indicating positive momentum [1] - The recent surge is attributed to the company's inaugural investor day and a prescription contracting agreement with Kroger [1] Group 2: Bumble Inc (BMBL) - Bumble stock is up 0.2% to $11.99, showing a notable uptrend since its record low of $9.83 on May 8 [2] - The stock has broken above several short-term moving averages, including the 60-day trendline, indicating a potential recovery [2] - Short interest represents 9.3% of BMBL's available float, suggesting some potential for a short squeeze [2] Group 3: Market Context - Both GoodRx and Bumble stocks exhibit short squeeze potential, with short interest at 10.8% for GDRX and 9.3% for BMBL [2]

RADNOR, Pa., May 15, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period"). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282- DDP-AJR was filed i ...

GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.While investors closely watch year-over-year changes in headline numbers -- revenue and earni ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The company's unaudited financial statements for Q1 2024 show key balance sheet, operations, equity, and cash flow data [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $1.45 billion while stockholders' equity declined to $631.1 million due to stock repurchases | (in thousands) | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $533,295 | $672,296 | | Total current assets | $732,799 | $872,790 | | Total assets | $1,453,963 | $1,588,800 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $116,521 | $122,559 | | Total liabilities | $822,894 | $826,842 | | Total stockholders' equity | $631,069 | $761,958 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2024 revenue grew to $197.9 million, but operating income fell to $7.4 million, with an improved net loss of $1.0 million | (in thousands, except per share amounts) | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Revenue | $197,880 | $183,986 | | Total costs and operating expenses | $190,499 | $172,683 | | Operating income | $7,381 | $11,303 | | Net loss | $(1,009) | $(3,290) | | Loss per share: Basic and diluted | $(0.00) | $(0.01) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Stockholders' equity decreased by $130.9 million to $631.1 million, primarily due to $154.8 million in stock repurchases - The company repurchased **21.3 million shares** of Class A common stock for **$154.8 million** during the three months ended March 31, 2024[21](index=21&type=chunk)[71](index=71&type=chunk) - Of the total repurchases, **20.9 million shares** were bought back from related parties (Spectrum and Francisco Partners) for an aggregate consideration of **$151.4 million**[22](index=22&type=chunk)[70](index=70&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow increased to $42.6 million, but significant financing outflows led to a $139.0 million net decrease in cash | (in thousands) | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Net cash provided by operating activities | $42,586 | $32,288 | | Net cash used in investing activities | $(20,615) | $(14,288) | | Net cash used in financing activities | $(160,972) | $(14,090) | | Net change in cash and cash equivalents | $(139,001) | $3,910 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes highlight customer concentration, a $27.5 million legal accrual, a new stock repurchase program, and revenue stream performance - For Q1 2024, **one customer accounted for 12% of revenue**; for Q1 2023, two customers accounted for 13% and 11% of revenue, respectively[40](index=40&type=chunk) - The company increased its accrued legal settlement to **$27.5 million** as of March 31, 2024, related to ongoing class action lawsuits concerning consumer privacy[47](index=47&type=chunk)[63](index=63&type=chunk) - In February 2024, the Board approved a new stock repurchase program authorizing up to **$450.0 million** of Class A common stock, with **$295.2 million remaining available** as of March 31, 2024[68](index=68&type=chunk) | (in thousands) | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Prescription transactions revenue | $145,395 | $134,907 | | Subscription revenue | $22,601 | $24,143 | | Pharma manufacturer solutions revenue | $24,509 | $20,435 | | Other revenue | $5,375 | $4,501 | | **Total revenue** | **$197,880** | **$183,986** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=14&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses an 8% revenue increase, improved net loss, growth in Adjusted EBITDA, and key operational metrics for Q1 2024 [Key Financial and Operating Metrics](index=15&type=section&id=Key%20Financial%20and%20Operating%20Metrics) Monthly Active Consumers grew to 6.7 million while subscription plans declined; Adjusted EBITDA increased to $62.8 million | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Monthly Active Consumers (millions) | 6.7 | 6.1 | | Subscription plans (thousands) | 778 | 1,007 | | Non-GAAP Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Adjusted EBITDA | $62.8 million | $53.2 million | | Adjusted EBITDA Margin | 31.7% | 28.9% | [Results of Operations](index=18&type=section&id=Results%20of%20Operations) Revenue grew 8% driven by prescription and pharma solutions, while operating expenses rose due to a legal settlement accrual - Prescription transactions revenue **grew 8% YoY**, driven by a **10% increase in Monthly Active Consumers**[99](index=99&type=chunk)[100](index=100&type=chunk) - Pharma manufacturer solutions revenue **increased 20% YoY** due to organic growth and expanded market penetration[102](index=102&type=chunk) - Subscription revenue **decreased 6% YoY**, primarily due to the anticipated sunset of the Kroger Savings program[101](index=101&type=chunk) - General and administrative expenses **increased by $11.5 million (39%)**, mainly due to a **$13.0 million estimated legal settlement loss** recognized in the quarter[106](index=106&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with $533.3 million in cash, despite significant cash use for stock repurchases - The company's principal sources of liquidity as of March 31, 2024, were **$533.3 million in cash and cash equivalents** and **$91.7 million available** under its revolving credit facility[112](index=112&type=chunk) - Net cash used in financing activities **increased by $146.9 million** year-over-year, primarily driven by a **$143.7 million increase** in payments for stock repurchases[120](index=120&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=21&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Market risk exposures remain materially unchanged from the 2023 Annual Report on Form 10-K - There have been **no material changes** in the company's market risk since the disclosure in the 2023 10-K[123](index=123&type=chunk) [Controls and Procedures](index=21&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective with no material changes to internal controls in Q1 2024 - Management concluded that as of March 31, 2024, the company's **disclosure controls and procedures were effective**[124](index=124&type=chunk) - There were **no changes in internal control over financial reporting** during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[125](index=125&type=chunk) [PART II. OTHER INFORMATION](index=21&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=21&type=section&id=Item%201.%20Legal%20Proceedings) The company details a $28.0 million accrual for privacy lawsuits and a new securities class action lawsuit filed in April 2024 - The company accrued an estimated probable loss of **$28.0 million** as of March 31, 2024, for ongoing consumer privacy class action lawsuits[63](index=63&type=chunk) - A **new class action lawsuit** was filed on April 22, 2024, alleging violations of the Exchange Act related to the company's disclosures about a "grocer issue" that occurred in 2022[64](index=64&type=chunk) [Risk Factors](index=21&type=section&id=Item%201A.%20Risk%20Factors) Risk factors remain materially unchanged from those disclosed in the 2023 Annual Report on Form 10-K - There have been **no material changes** to the risk factors previously disclosed in the 2023 10-K[128](index=128&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=21&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company details its Q1 2024 stock repurchases of $154.8 million and the remaining use of IPO proceeds - As of March 31, 2024, an estimated **$460.5 million of net proceeds from the IPO remained**, which have been invested in investment-grade, interest-bearing instruments[131](index=131&type=chunk) | Period | Total Number of Shares Repurchased | Average Price Paid per Share | Approximate Dollar Value of Shares that May Yet Be Repurchased (in thousands) | | :--- | :--- | :--- | :--- | | March 1 - 31, 2024 | 21,329,492 | $7.26 | $295,185 | [Defaults Upon Senior Securities](index=22&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported during the period - None[134](index=134&type=chunk) [Mine Safety Disclosures](index=22&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company's operations - Not applicable[135](index=135&type=chunk) [Other Information](index=22&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 trading plans during the first quarter of 2024 - During the three months ended March 31, 2024, **none of the company's directors or officers adopted or terminated** any contract, instruction or written plan for the purchase or sale of securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)[136](index=136&type=chunk) [Exhibits](index=23&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including agreements and certifications

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.08, delivering no surprise.Over the last four quarters, the company ha ...

Exhibit 99.1 GOODRX REPORTS FIRST QUARTER 2024 RESULTS SANTA MONICA, Calif. -- (May 9, 2024) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Exhibit 99.1 Revenue and Adjusted Revenue increased 8% to $197.9 million compared to $184.0 million. Prescription transactions revenue increased 8% to $145.4 million compar ...